OnCo
ideasIdea

Anchor a TGF-beta trap in the tumour stroma so it cannot act everywhere

A powerful immune-suppressing signal called TGF-beta keeps immune cells out of tumours, but blocking it throughout the body causes heart and skin problems. Tethering the blocker inside the tumour could give benefit without the harm.

Systemic TGF-beta blockade, including the PD-L1-TGF-beta trap bintrafusp alfa, failed largely on a narrow therapeutic index with bleeding and cardiac toxicity. Localisation strategies — a FAP-anchored trap, a collagen-binding domain fusion, or a protease-activated masked format — restrict activity to stroma-rich tumour tissue, and masked antibody formats are already in clinical trials.

Hypothesis
A stroma-anchored TGF-beta trap achieves at least tenfold higher tumour-to-plasma target engagement than an unanchored trap and increases T-cell penetration into the tumour core without cardiovascular toxicity.
Rationale
TGF-beta is one of the best-validated barriers to T-cell infiltration in human tumours, notably in urothelial cancer where a stromal TGF-beta signature predicts checkpoint failure. The failure of systemic agents is an index problem, and localisation is the standard fix.
What would test it
Preclinical head-to-head of anchored versus systemic trap for exposure ratio and toxicity, then a phase 1 with paired biopsies measuring stromal phospho-SMAD2 suppression and CD8 distribution relative to stroma.
Maturity
preclinical evidence
Who has to act
industry
Cost to try
Medium ($1M to $50M)
Years to first evidence
7
Bottlenecks it attacks

Connected

11top

Pages like this

not linked directly; found by shared links